Introduction
The carcinogenicity of vinyl chloride and its predilection for the hepatic blood vessels of both experimental animals and man is now well recognized, and the substance is rightly regarded as a serious hazard in the workplace. Moreover, the demonstration by Maltoni (1) that vinyl chloride is not only carcinogenic for adult rodents but is a transplacental carcinogen for the rat as well, has raised concern over a possible risk of carcinogenesis in children born to mothers who had been employed in vinyl chloride manufacturing during their pregnancy. In the United States this has also led to questions of whether it is reasonable to single out women in the workplace as individuals especially at risk and whether to do so unfairly infringes upon their rights to equality in employment. It has been asked whether men may not equally be at risk in terms of the potential of workplace exposure to vinyl chloride and related compounds to cause genetic damage in workers so exposed, and in this *Perinatal Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute, Fort Detrick, Frederick, Maryland 21701. October 1981 indirect way to contribute to an increased risk of cancer in their offspring. These are important questions, not all of which can be fully answered at the present time. Our laboratory has not been engaged in research on vinyl chloride and therefore can contribute no new data to what has been presented during the course of this conference. However, we have been engaged for many years in studying the phenomena of prenatal carcinogenesis by a variety of chemical carcinogens and in species as diverse as the mouse and subhuman primates, and it is the purpose of this presentation to provide a context of current knowledge about the phenomena of prenatal carcinogenesis within which the risk of prenatal exposure to this agent and related compounds can be evaluated.
Mechanisms of Chemical Carcinogenesis
When one tests a substance or a mixture of substances for carcinogenic activity in rodents, a positive result commonly takes one or more of the following three forms: (1) When one compares the dose-response relationships for offspring of rats treated on day 15 of gestation with the response of adult rats to the same agent, it is found that the offspring are approximately 50-fold more susceptible than adults to the carcinogenic effects of this agent: the dose necessary to induce one or more neurogenic tumors in 50% of exposed adult rats is on the order of 150 mg/kg, but the corresponding dose for transplacentally exposed offspring is approximately 3 mg/kg (calculated on the basis of the mother's total body weight).
If exactly the same sort of experiment is conducted in the mouse, however, the results are qualitatively much different. Tumors of the nervous system are relatively rare in mice following transplacental exposure to ENU. As in rats, however, transplacentally treated offspring exposed on or after day 12 of gestation develop tumors. In contrast to rats, mice exposed transplacentally to ENU develop epithelial tumors of the lung and hepatocellular tumors of the liver in high incidence and multiplicity (8) . In both species, the fetus is quantitatively more susceptible than the adult: susceptibility is greatest during the second half of the period of gestation, and increases as gestation proceeds towards parturition. Adult animals are less sensitive, by one to two decimal orders of magnitude, to the carcinogenic effects of ENU. This much higher prenatal susceptibility is one of the principal reasons for concern that transplacental exposure to carcinogens in the mother's workplace or environment may be of significant risk for the human fetus. (9) , but that it causes tumors principally of the vascular connective tissues and to a lesser extent the liver, kidney and brain, a pattern of response different from either the rat or the mouse. Tumor incidence is higher and latency is shorter in offspring than in pregnant or nonpregnant treated adults; in that respect the pattern resembles that seen in both rodent species, but neither the rat or the mouse yields a spectrum of tumors predictive of the results of exposing monkeys to the same agent. In our experiments pregnant patas monkeys were exposed to ENU during either the first half or the second half of gestation, or throughout pregnancy. It has become strikingly apparent that animals exposed for the first time at day 30 are at much higher risk for tumor development than animals given comparable exposure but beginning even 30 days later in gestation. This marks a significant departure from the patterns seen in rodents and suggests that the period of maximum intrinsic susceptibility to chemical carcinogens in other primates, including man, may well be during the first trimester of pregnancy and in that respect may resemble the period of greatest susceptibility to teratogens. Obviously, this includes the early fraction of gestation during which, at the time of possibly greatest vulnerability of her conceptus, a woman may not know for certain that she is pregnant and may therefore not be warned to take special precautions to prevent exposure to noxious agents.
In other important respects, such as the greater susceptibility of the fetus, experience in the patas monkey is comparable to that in the rat and mouse and suggests that the phenomenon of high fetal susceptibility to carcinogens is a general one. The fact that the organ systems principally affected by ENU in this species are different from those of the rodent species further emphasizes that one should be extremely cautious in extrapolating from any other species to man in predicting the site of action of a chemical carcinogen, even a direct acting one. The one common pattern valid across species lines 182 in the matter of prenatal organ specificity is that the nervous system and the kidneys appear to be susceptible to at least some extent to this agent in all species tested, an observation which brings to mind the fact that tumors of the kidney and nervous system predominate among solid tumors of childhood.
Transplacental Carcinogenesis by Metabolism-Dependent Carcinogens
The vast majority of genotoxic chemical carcinogens are not direct-acting, but, as indicated previously, require metabolic conversion to a chemically reactive ultimate carcinogen in order to effect carcinogenesis. It has been shown that in rodents, the mixed function oxidase enzymes principally involved in activation of chemical carcinogens are present at low or virtually undetectable levels in fetal tissues until immediately prior to parturition, and even then are present at levels that are minuscule in comparison with those in adult tissues (10) . The picture is complicated by the fact that these enzymes are inducible, and their levels in tissues such as the liver may be significantly altered by exposure to chemical agents that are substrates for these enzymes, including carcinogens such as methylcholanthrene (3) . The role of enzyme induction in modifying fetal susceptibility to transplacental carcinogens has not yet been well studied and remains conjectural. However, the low levels of enzymes present in noninduced fetal rodent tissues result in extremely inefficient conversion of most substances to reactive ultimate carcinogenic metabolites. Thus, when the chemically reactive metabolite is very unstable, i.e., has an extremely short half-life under physiologic conditions, it cannot be effectively generated in maternal tissues and transported via maternal and fetal-bloodstreams to fetal tissues. Very short-lived reactive metabolites must be generated in situ in any fetal tissue in which carcinogenesis is to occur. Agents whose carcinogenicity is mediated by such metabolites are extremely poor transplacental carcinogens. An example is dimethylnitrosamine (DMN; Fig. 2 ). DNM is metabolized by mixed function oxidases by the N-dealkylation mechanism, generating an intermediate methyl(hydroxymethyl)-nitrosamine which is far too unstable to demonstrate even spectroscopically. It has never been synthesized. This is an excellent example of an agent which presumably must be formed by fetal enzymes. When the parent compound, DMN, was tested for transplacental carcinogenic activity it was found as expected to be much less efficient in offspring than in their mothers in the induction of tumors of the kidney (11 Figure 3 . The arene oxides, dihydrodiol, and diolepoxide (Fig. 3) October 1981 genic potency in experimental animals (13, 14) . Accordingly, it is quite possible that metabolites of this sort may be formed in maternal tissues and may succeed in traversing the maternal bloodstream and placenta to reach the fetus. When the parent hydrocarbon DMBA was tested for transplacental carcinogenicity in rats by using a foster nursing procedure (15) , it was found to be extremely potent. The experiment was terminated at 52 weeks with only 20% of the offspring still surviving; large numbers of tumors were seen in the central and peripheral nervous systems, the kidneys, and blood vessels, as well as in other sites. Thus, not only is this particular metabolism dependent agent a potent transplacental carcinogen, but it actually affects a broader spectrum of organ systems in the fetus of the rat than the extremely potent direct acting carcinogen ENU.
Metabolism and Carcinogenicity of Vinyl Chloride
The carcinogenicity of vinyl chloride for rats, mice, and hamsters over an extremely wide range of doses as well as its transplacental carcinogenic effects in rats, are presented by Maltoni (16) ; an earlier version of his data for rats (1) is summarized in Table 1 . It can be seen that on inhalation of vinyl chloride, tumors are induced in dose-dependent fashion in adult rats in the liver, nasal cavity, kidneys, Zymbal's gland, and most importantly and consistently, in the blood vessels, especially those of the liver. Transplacental exposure for a period of one week, between the 12th and 18th days of pregnancy, generated tumors in three of the,se tissues, the kidney, blood vessels, and Zymbal's gland, in the offspring (Table 2) . Although no controls were included specifically in the transplacental study, the very large series of historical control animals carefully examined in that laboratory are convincing proof that the elevated incidence of tumors of these three tissues is real, and that vinyl chloride is effectively a transplacental carcinogen in the rat. It is noteworthy that the sites and kinds of tumors in-183 duced by vinyl chloride are different in part from those that resulted from transplacental exposure to any of the agents discussed previously, none of which affected the Zymbal's glands. The tissues and organs affected in offspring exposed transplacentally to vinyl chloride included some but not all those in which tumors developed in adults subjected to much more prolonged exposures (cf . Tables 1 and  2) , and in the transplacental study, significant numbers of tumors were induced in the offspring but not in the mothers. Vinyl chloride is a metabolism-dependent carcinogen, dependent for its carcinogenicity on mixed function oxidases (17) which convert vinyl chloride to its epoxide derivative chloroethylene oxide (chlorooxirane, Fig. 4 ). The carcinogencity of chloroethylene oxide and of its rearrangement product, chloroacetaldehyde, were recently investigated by researchers at the International Agency for Research on Cancer in Lyon, France, who tested both compounds by subcutaneous injection and by skin painting, the latter followed by phorbol ester promotion, in mice. Chloroethylene oxide proved to be an effective carcinogen, inducing both papillomas and carcinomas in the skin and giving rise to sarcomas on injection (Table 3) . Its rearrangement product, chloroacetaldehyde, was toxic, but not demonstrably carcinogenic (18) . It was noted by the IARC investigators is that the half-life of chloroethylene oxide for hydrolysis at 370 C is on the order of 0.9 min. This is sufficient time for chloroethylene oxide formed in maternal tissues to reach the fetus by way of the placenta, and provides strong suggestive evidence that maternal metabolism contributes to transplacental carcinogenicity of vinyl chloride. To date, however, chloroethylene oxide has not itself been tested for transplacental carcinogencity.
Analogs of Vinyl Chloride
It is important to note that vinyl chloride is by no means unique with respect to chemical structure, and that a wide variety of compounds are in current use in large volumes in industrial processes which differ from vinyl chloride only by further substitution of the vinyl chloride molecule. A partial list of such substances is given in Table 4 . Furthermore bOriginally reported (1) as neuroblastoma of the brain. Tables 4 and 5 have been reviewed for risk of carcinogenicity to man in the IARC monograph series (22, 23) . Other compounds 185 The experimental data which are relevant to this question generally concern what has been termed the "second generation effect" in prenatal carcinogenesis, which has been reviewed by Tomatis (25 The incidence of tumors that will develop in a given organ system following transplacental exposure to a carcinogen is not necessarily the maximum incidence possible. Cocarcinogenic phenomena, in which exposure to a second, noncarcinogenic agent accelerates the development and increases the yield of tumors resulting from a previous carcinogenic exposure, are well demonstrated in transplacental carcinogenesis (26) , especially in the mouse where they have been documented for the skin and for the liver. Potential tumor cells may remain quiescent for prolonged periods after exposure to the inducing agent, and in evaluating the significance of transplacental exposure one must bear in mind that subsequent, postnatal exposure to noncarcinogenic promoting agents may act in a strongly synergistic fashion with prenatal exposure to a carcinogen and may greatly increase the risk of carcinogenesis.
Finally, all agents known to be prenatal-that is, transplacental-carcinogens are also carcinogenic to some extent during postnatal life in one or more species. To some extent, this is a consequence of the manner in which the science of transplacental carcinogenesis has developed; known carcinogens have been selected for testing for transplacental effects. Nonetheless, the generalization holds that there is no known purely transplacental carcinogen.
